BRAF-mutant tumors (60–70% of thyroid cancers) are more likely to be resistant to radioiodide, partly due to decreased NIS expression (13,45), but also due to impaired PM targeting (11,14) through mechanisms that remain ill-defined. This evidence concerns the gene BRAF and thyroid gland carcinoma.